Advertisement
Research ArticleArticle

DEVELOPMENT OF AN IN VIVO PRECLINICAL SCREEN MODEL TO ESTIMATE ABSORPTION AND FIRST-PASS HEPATIC EXTRACTION OF XENOBIOTICS. II. USE OF KETOCONAZOLE TO IDENTIFY P-GLYCOPROTEIN/CYP3A-LIMITED BIOAVAILABILITY IN THE MONKEY

Keith W. Ward, Gary J. Stelman, Jayme A. Morgan, Kelli S. Zeigler, Leonard M. Azzarano, Jonathan R. Kehler, Jeanelle E. McSurdy-Freed, Joel W. Proksch and Brian R. Smith
Drug Metabolism and Disposition February 2004, 32 (2) 172-177; DOI: https://doi.org/10.1124/dmd.32.2.172

Article Information

vol. 32 no. 2 172-177
DOI 
https://doi.org/10.1124/dmd.32.2.172
PubMed 
14744938
Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Received June 30, 2003
  • Accepted September 26, 2003
  • Published online January 26, 2004.
Copyright & Usage 
The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Keith W. Ward,
  2. Gary J. Stelman,
  3. Jayme A. Morgan,
  4. Kelli S. Zeigler,
  5. Leonard M. Azzarano,
  6. Jonathan R. Kehler,
  7. Jeanelle E. McSurdy-Freed,
  8. Joel W. Proksch and
  9. Brian R. Smith
  1. Preclinical Drug Discovery, Cardiovascular & Urogenital Centre of Excellence in Drug Discovery, GlaxoSmithKline, King of Prussia, Pennsylvania
  1. Address correspondence to:
    Dr. Keith W. Ward, Preclinical Drug Discovery, Cardiovascular & Urogenital CEDD, GlaxoSmithKline, UW 2725, 709 Swedeland Road, King of Prussia, PA 19406. E-mail: Keith_W_Ward{at}GSK.com
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: August 2017 to December 2024

AbstractFullPdf
Aug 20170153
Sep 2017173
Oct 20171218
Nov 20171259
Dec 20174125
Jan 20181134
Feb 20180114
Mar 20184169
Apr 20182114
May 20182911
Jun 20181193
Jul 201811410
Aug 20180128
Sep 20182104
Oct 2018065
Nov 2018492
Dec 2018641
Jan 2019400
Feb 20191543
Mar 20191200
Apr 20191903
May 2019820
Jun 20191012
Jul 20192800
Aug 20191400
Oct 20191123
Nov 20191300
Dec 20192142
Jan 20201321
Feb 2020900
Mar 20201211
May 20204912
Jun 2020900
Jul 2020500
Aug 2020312
Sep 20201130
Oct 20202943
Nov 20201510
Dec 20202320
Jan 2021760
Feb 20211271
Mar 20212653
Apr 2021920
May 2021841
Jun 20212070
Jul 2021810
Aug 2021550
Sep 2021721
Oct 20211330
Nov 20212110
Dec 20211410
Jan 2022822
Feb 20221053
Mar 20221410
Apr 20221020
May 20221610
Jun 20221310
Jul 2022813
Aug 20221733
Sep 2022820
Oct 20221220
Nov 20221911
Dec 20221133
Jan 20232531
Feb 20231330
Mar 2023721
Apr 2023710
May 20232420
Jun 2023911
Jul 2023932
Aug 20231051
Sep 20231320
Oct 20231010
Nov 20231810
Dec 20233860
Jan 20241121
Feb 2024611
Mar 20241131
Apr 20242372
May 20241643
Jun 20241841
Jul 20241551
Aug 20241410
Sep 20242633
Oct 20241521
Nov 2024900
Dec 2024801

Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleArticle

DEVELOPMENT OF AN IN VIVO PRECLINICAL SCREEN MODEL TO ESTIMATE ABSORPTION AND FIRST-PASS HEPATIC EXTRACTION OF XENOBIOTICS. II. USE OF KETOCONAZOLE TO IDENTIFY P-GLYCOPROTEIN/CYP3A-LIMITED BIOAVAILABILITY IN THE MONKEY

Keith W. Ward, Gary J. Stelman, Jayme A. Morgan, Kelli S. Zeigler, Leonard M. Azzarano, Jonathan R. Kehler, Jeanelle E. McSurdy-Freed, Joel W. Proksch and Brian R. Smith
Drug Metabolism and Disposition February 1, 2004, 32 (2) 172-177; DOI: https://doi.org/10.1124/dmd.32.2.172
Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement